News

News

Pharm-Olam Conducts Pivotal Orphan Disease Trial, Leads to First Therapeutic Approved for the Treatment for Acquired Thrombotic Thrombocytopenic Purpura

Tuesday, October 30, 2018

Houston, Oct. 30, 2018 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Pharm-Olam is proud to have contributed to the execution and completion of its pivotal Phase III study.

Pharm-Olam Unifies Data on Medidata Cloud, Eliminating Silos

Wednesday, October 24, 2018

CRO accelerates the delivery of life-changing therapies with a single view of data for all clinical trial stakeholders

Pharm-Olam International Supports Clinical Trials and Sponsors Compliance with GDPR

Tuesday, July 31, 2018

Houston, July 31, 2018Pharm-Olam International, a global, full-service contract research organization (CRO) specializing in oncology, infectious diseases and vaccines, rare and orphan diseases, provides multiple resources for life science organizations to comply with the new European Union General Data Protection Regulation (GDPR). Pharm-Olam provides education and consultation on how the GDPR affects clinical trial conduct and also works directly with companies to achieve compliance.

Pharm-Olam International Invites Pharmaceutical and Biotechnology Professionals to Its May 15th Live Webinar in Preparation for the GDPR Implementation Across Global Clinical Trial Industry

Friday, April 27, 2018


HOUSTON, Tx. — April 26, 2018. Pharm-Olam International, a global, full-service Contract Research Organization (CRO) specializing in Oncology, Infectious Diseases & Vaccines, Rare Diseases and Pediatric indications, is prepared for the implementation of the European Union’s (EU’s) General Data Protection Regulation (GDPR), which will impact our industry among others where organizations collect and hold personal data on EU citizens.  Utilizing Pharm-Olam’s version of the Bow Tie Methodology for visual risk assessment and management, powered by Ideagen’s Q-Pulse software, Pharm-Olam is fully prepared for the global GDPR roll-out. In anticipation of GDPR’s effective date (May 25, 2018), Pharm-Olam will be hosting an interactive 60-minute live training webinar on May 15, 2018 at 11a.m. EST for its pharmaceutical and biotechnology partners and clients.  Registration and attendance is open to the public.  

Pharm-Olam International Appoints Industry Veteran Dr. Kelly McKee as Chief Medical Officer; Enhances Infectious Disease & Vaccine Competencies

Thursday, January 11, 2018

Pharm-Olam International, a multinational, full-service Clinical Research Organization (CRO) specializing in Oncology, Infectious Diseases, Rare Diseases and Pediatric indications, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H. as Chief Medical Officer (CMO).

Pharm-Olam International Named Winner in CRO Leadership Awards for Second Consecutive Year

Tuesday, June 13, 2017

HOUSTON, TX – Pharm-Olam International LLC, an award-winning, multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the company has been selected as a winner in Life Science Leader magazine’s 2017 CRO Leadership Awards.

Pharm-Olam International Adds Key Strategic Personnel, Names John Barry as Chief Operating Officer

Wednesday, May 31, 2017

HOUSTON, TX – Pharm-Olam International LLC, a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of John Barry as Chief Operating Officer.

Pharm-Olam Experts to Present Live Seminar on Evolution of Response Evaluation in Oncology Trials

Thursday, March 23, 2017

Global clinical research experts Yamin “Mo” Khan, PhD, and Dhiraj Abhyankar, MD will host an interactive discussion and seminar on the Evolution of Response Evaluation in Oncology Trials. The free public forum will be held at 11 a.m. Eastern Standard Time on Thursday, March 30 via webinar.

Global CRO Pharm-Olam International Announces New Addition to Lead Biostatistics Team

Wednesday, February 22, 2017

HOUSTON, TEXAS – Pharm-Olam International LLC, a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of Julia Graz as Senior Director, Biostatistics.

Quad-C Management Announces Investment in Pharm-Olam International

Thursday, February 09, 2017

Charlottesville, VA. – Quad-C Management, Inc. (“Quad-C”), a leading middle market private equity firm, today announced it has closed an investment in Pharm-Olam International Ltd., a multinational, full-service clinical research organization (CRO), serving the biopharmaceutical and medical device industries. Terms of the transaction were not disclosed.